Correction to: An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial
Journal: Circulation (2024)

a correction is needed.It has come to the author's attention that….• Errors were identified in the number of patients with diabetes in Table 1.• Errors were identified in the number of patients with diabetes with insulin and diet only in Table S1.• Errors were also identified in the number of patients with diabetes and those with insulin and diet only stratified by acute coronary syndrome (ACS) and non-ACS in Table S2.• Consequently, errors were identified in the subgroup analysis for the effect of no-aspirin relative to DAPT on the co-primary end points in patients with diabetes and diabetes with insulin in Figure 4.The article has been updated to show:• The number of patients with diabetes was updated from 2427 (no-aspirin group: 1202 and DAPT group: 1225) to 2715 (no-aspirin group: 1355 and DAPT group: 1360) in Table 1.• The numbers of diabetic patients with insulin and diet only were updated from 320 (no-aspirin group: 150 and DAPT group: 170) to 321 (no-aspirin group: 151 and DAPT group: 170) and from 676 (no-aspirin group: 339 and DAPT group: 337) to 954 (no-aspirin group: 485 and DAPT group: 469) respectively, in Table S1.• The number of patients with diabetes was updated from 1678 (no-aspirin group: 831 and DAPT group: 847) to 1924 (no-aspirin group: 960 and DAPT group: 964) in patients with ACS and from 749 (no-aspirin group: 371 and DAPT group: 378) to 791 (no-aspirin group: 395 and DAPT group: 396) in patients with non-ACS in Table S2.• The number of diabetic patients with insulin was updated from 147 (no-aspirin group: 68 and DAPT group: 79) to 148 (no-aspirin group: 69 and DAPT group: 79) in patients with non-ACS in Table S2.• The numbers of diabetic patients with diet only were updated from 541 (no-aspirin group: 270 and DAPT group: 271) to 781 (no-aspirin group: 395 and DAPT group: 386) in patients with ACS and from 135 (no-aspirin group: 69 and DAPT group: 66) to 173 (no-aspirin group: 90 and DAPT group: 83) in patients with non-ACS in Table S2.• In subgroup analysis for diabetes regarding co-primary bleeding end point, cumulative incidence (4.93% and 5.17%), absolute difference (-0.24%; 95% CI, -2.08% to 1.60%) and hazard ratio (HR) (0.95; 95% CI, 0.67-1.36) of the no-aspirin group relative to the DAPT group in patients with diabetes were updated to the following: cumulative incidence (5.05% and 5.47%), absolute difference (-0.42%; 95% CI, -2.19% to 1.35%) and HR (0.92; 95% CI, 0.66-1.28).Cumulative incidence (4.16% and 4.39%), absolute difference (-0.23%; 95% CI, -1.62% to 1.16%) and HR (0.95; 95% CI, 0.69-1.30) of the no-aspirin group relative to the DAPT group in patients without diabetes were updated to the following: cumulative incidence (3.99% and 4.07%), absolute difference (-0.08%; 95% CI, -1.49% to 1.33%) and HR (0.98; 95% CI, 0.69-1.38).P for interaction was updated from 0.97 to 0.81 in Figure 4A.• In subgroup analysis for diabetes regarding co-primary cardiovascular end point, cumulative incidence (5.08% and 4.98%), absolute difference (0.10%; 95% CI, -1.73% to 1.93%) and HR (1.02; 95% CI, 0.72-1.46) of the no-aspirin group relative to the DAPT group in patients with diabetes were updated to the following: cumulative incidence (5.54% and 5.15%), absolute difference (0.39%; 95% CI, -1.40% to 2.18%) and HR (1.08; 95% CI, 0.78-1.49).Cumulative incidence (3.48% and 2.79%), absolute difference (0.69%; 95% CI, -0.49% to 1.87%) and HR (1.25; 95% CI, 0.86-1.82) of the no-aspirin group relative to the DAPT group in patients without diabetes were updated to the following: cumulative incidence (2.95% and 2.47%), absolute difference (0.48%; 95% CI, -0.66% to 1.62%) and HR (1.20; 95% CI, 0.79-1.82).P for interaction was updated from 0.44 to 0.70 in Figure 4B.